Relationship between Ribosomal Protein S6-pS240 Expression and other Prognostic Factors in Non-Special Type Invasive Breast Cancer (original) (raw)
Related papers
2018
Prognosis and management of patients with invasive breast carcinoma, NST is dependant on a few established parameters such as: TNM stage, Nottingham Prognostic Index, age, Estrogen and Progesterone Receptor expression, Her-2/neu amplification, proliferation index as measured by Ki67 and molecular profiling. In our study we analyzed immunohistochemical expression of Estrogen Receptor, Progesterone Receptor, Her-2/neu, Ki-67 and p53 in in patients classified according to Nottingham Prognostic Index, TNM stage and age. In patients classified according to the original Nottingham Prognostic Index there was significant difference in biomarker expression. In contrast, this difference was not observed when patients were classified according to TNM. In analysis of marker expression in different age groups, significant difference was observed only with p53, expression of which was seen more frequently in younger age group. In conclusion, prognostic stratification of patients by the original N...
A study on molecular subtype of breast carcinoma using ER, HER2, PR, and its relation with Ki67
Journal of Clinical and Basic Research (JCBR), 2023
Background: Using molecular biomarkers of breast cancer (BC) receives optimal treatment. Established biomarkers like estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 may play significant roles in the sub-categorization of BC to predict the prognosis and specific therapy for each patient. This study aims to characterize breast carcinoma using molecular markers (ER, PR, and HER2 neu), identify their sub-types, and attain its relation with Ki67. Methods: This cross-sectional (retrospective) study was conducted over four years at the Department of Pathology, SVS Medical College, Mahabubnagar, from April 2018 to March 2022. Fifty diagnosed cases of breast carcinomas were subjected to routine staining and immunohistochemistry (IHC) with ER, PR, HER 2 neu, and Ki67 using tissue microarray and classified into molecular subtypes. Results: In this study, 32% of participants were in the 50-59 age group. The right breast was involved in 52% of participants. The central quadrant was involved in 44%, UOQ 32%, UIQ 16%, and LOQ 8%. Moderately differentiated tumors exist in 40%, poorly differentiated in 36%, and well-differentiated in 24%. 84% of patients were ER-positive, 70% were PR-positive, and 72% were HER2/neu-positive. 28% of patients with positive Ki-67 were grade I, 22% were grade II, and 50% were grade III. Her2/neu contributed to 12% and triple-negative BC seen in 4%. The association between the ER status and Ki-67 positivity status is not statistically significant, with a P-value of 0.13. The association between the PR status and Ki-67 positivity status is statistically significant, with a P-value of 0.002. The association between the Her2/neu status and Ki-67 positivity status is also statistically significant, with a P-value of <0.0001. Conclusion: Most cases were Ki67 positive and HER2 neu positive. Triple-negative cases showed a high Ki67 index. Ki67 plays a pivotal role in making treatment decisions. The Ki67 index is independent and can be used independently without being correlated with other indices, and Ki67 should be evaluated routinely in breast carcinoma cases.
2020
Background: Breast carcinoma is one of the leading causes of mortality and morbidity in middle aged females. Numerous histomorphological prognostic factors including hormonal receptor status play vital role in further management of patient care. Objectives: This study was undertaken with the aims and objectives to study the correlation of tumor size, tumor grade and regional lymph node metastasis with hormone receptors(ER, PR and HER2). Materials and methods: This is a retrospective study; all patients diagnosed with Invasive breast carcinoma-NST within June2013-Sep2015 were included. MRM specimen’s gross and microscopic finding were collected and studied. Results: Total 141 patients were studied. Maximum numbers of patients were from 5 th decade, left sided tumor was found in 61%cases. Tumor size of 2.1-5cm was found in 58.9% cases. Axillary lymph node metastasis was found in 54.6% cases. Statistically significant association of ER/PR was found with Tumor size (P 0.041) and with Ax...
Medicina, 2020
Background and objectives: Our aim is to explore the relationship between the levels of protein encoded by Ki67 and the histopathological aspects regarding the overall survival and progression-free survival in a single university center. A secondary objective was to examine other factors that can influence these endpoints. New approaches to the prognostic assessment of breast cancer have come from molecular profiling studies. Ki67 is a nuclear protein associated with cell proliferation. Together with the histological type and tumor grade, it is used to appreciate the aggressiveness of the breast tumors. Materials and Methods: We conducted a retrospective single-institution study, at Elias University Emergency Hospital, Bucharest, Romania, in which we enrolled women with stage I to III breast cancer. The protocol was amended to include the immunohistochemistry determination of Ki67 and the histological aspects. The methodology consisted in using a Kaplan–Meier analysis for the entire...
Cancer Chemotherapy and Pharmacology, 2019
Purpose Many studies have indicated that the response to therapy and the prognostic impact of a pathologic complete response after neoadjuvant treatment differ among breast cancer subtypes. Methods The aim of our study is to evaluate the effect of this treatment on the expression of estrogen and progesterone receptors, human epidermal growth hormone receptor 2 and Ki67 in breast cancer. We identified 125 patients. Results The estrogen receptor modified its expression from positive to negative in 8% patients and from negative to positive in 22%; progesterone in 21% and in 37% cases. Median Ki-67 value was 20.9% at biopsy and 18% after, HER-2 status did not show a remarkable change before or after neoadjuvant chemotherapy (NACT). We have identified a significant reduction in Ki-67 expression levels after chemotherapy in patients with a pathologic response. Detection of pretreatment Ki-67 could identify patients most likely to benefit from NACT. Conclusions NACT can change the status of ER, PgR, and Ki-67 expression in patients with breast adenocarcinoma, but it did not exert a significant effect on HER-2 status; HER-2 amplification appears to be more stable. We have identified a prognostic role for a decreased expression of PgR and Ki-67 after preoperative chemotherapy in breast cancer patients.
Asian Pacific Journal of Cancer Prevention, 2014
Background: The prognostic value of the Ki67 expression level is yet unclear in breast cancer. The aim of this study was to investigate the association between Ki67 expression levels and prognostic factors such as grade, Her2 and hormone receptor expression status in breast cancers. Materials and Methods: Clinical and pathological features of the patients with breast cancer were retreived from the hospital records. Results: In this study, 163 patients with breast cancer were analyzed, with a mean age of 53.4±12.2 years. Median Ki67 positivity was 20% and Ki67-high tumors were significantly associated with high grade (p<0.001), lymphovascular invasion (p=0.001), estrogen receptor (ER) negativity (p=0.035), Her2 positivity (p=0.001), advanced stage (p<0.001) and lymph node positivity (p<0.003). Lower Ki67 levels were significantly associated with longer median relapse-free and overall survival compared to those of higher Ki67 levels. Conclusions: High Ki67 expression is associated with ER negativity, Her2 positivity, higher grade and axillary lymph node involvement in breast cancers. The level of Ki67 expression is a prognostic factor predicting relapse-free and overall survival in breast cancer patients.
Cancer genomics & proteomics, 2005
Metallopanstimulin (MPS-1)/S27 ribosomal protein is involved in cellular proliferation and oncogenesis. In this study, we have examined the expression of the MPS-1 protein in 120 stages I and II breast carcinomas to study its relationship with breast cancer prognosis. We also determined if there was any relationship of MPS-1 with other biological markers commonly used in breast cancer prognosis. The expression of MPS-1 protein was analyzed by immunohistochemistry using specific anti-MPS-1 antibodies. We found that there was greater expression of MPS-1 in tumors of greater size and in higher histological grades. Thus, in tumors with more histological aggressiveness there is more MPS-1. Both were frequently associated with a greater proliferative activity. There was also a significant association between the expression of MPS-1 with the expression of receptors for progesterone (p=0.004), estrogens (p=0.03), bcl-2 (p=0.002), and MIB-1 (p=0.03). After univariate logistic regression anal...
Prognostic values of proliferative markers ki-67 and repp86 in breast cancer
Archives of Iranian Medicine, 2007
Background: Breast cancer is the leading cause of carcinoma death in women. Proper treatment depends on the consideration of molecular biology status of tumor cells, which may determine the patient's treatment and prognosis. To determine the prognostic models for this disease, we evaluated the role of cell proliferation-related antigens including ki-67 (a nuclear antigen, expressed in G1, G2, and M phases of cell cycle) and repp86 (an 86-kDa nuclear protein expressed in S, G2, and M phases of cell cycle) for detection of biologic behavior of breast cancer. Methods: We studied 60 women with grade I and II lymph node-negative and 27 with grade III lymph node-positive breast cancers. The mean follow-up periods for these two groups were 60 and 72 months, respectively. Tumor cell proliferation was measured by immunohistochemical methods with monoclonal antibodies directed against the nuclear antigens ki-67 and repp86. Results: The ki-67, repp86 labeling indices (percentage of antibody-stained tumor cell nuclei) were not statistically different between the cases and controls of lymph node-negative patients (ki-67 with P = 0.33; repp86 with P = 0.40). The odds ratio (the mean chance of ki-67 labeling index > 10%, repp86 labeling index >10%) in patients with recurrence was 4 (CI = 0.2-76.5) for ki-67 and 3.6 (CI = 0.4-32.5) for repp86. Both indices were statistically different in lymph node-positive cases and controls (P < 0.0001). The odds ratio in patients with recurrence was 87 (CI = 4-18.71) for ki-67 and 71.5 (CI = 5.7-899.2) for repp86. Conclusion: The present study confirms the importance of cell proliferation as a determinant of biologic behavior of breast cancer. Measurement of ki-67 and repp86 labeling indices may be very helpful for physicians to detect high-risk patients and to adopt appropriate procedure such as adjuvant therapy.
To Study Clinicopathological Correlation of Ki67 in Invasive Breast Cancer
IOSR Journals , 2019
Introduction-Ki67 expression is a biomarker for proliferation. Expression of ki 67 and its Association with other prognostic factors in breast cancer is recognised significantly. Aim-(1) To classify breast cancer on the basis of Ki 67 and hormone status(molecular subtypes).(3)To correlate ki67 with other clinicopathological parameters. Method-77 breast cancer women with invasive ductal carcinoma(MRM specimen) were included in this study. Hormone receptor status, HER2 status and ki67 index were determined for breast cancer subtype. Age, tumor size, lymph node involvement, histological grade, nuclear grade, and lymphovascular invasion were evaluated and correlated with Ki67 index. Statistics used-Chi square test Results-In our study with 77 breast cancer patients, patients with age>50 years , 26 cases show more than 20% ki67 index in comparison 9 cases show <20% positivity. After analysing the histological grade with ki67 index , 54 cases having histological grade 2 & 3 showing > 20% Ki67 index. Hormonal receptor her2/ neu expression was directly correlated with ki67 index. In her2 neustudy , out of 26 positive cases, 22 cases showed >20%. While there is significant inverse correlation between Ki67 with ER and PR status of patients. Conclusion-Patients with low ER and PR expression have higher value of ki67. Other factors eg. Older age, tumor size , higher histological and nuclear grade, Her2/neu positivity are also correlated with increased Ki67 index. Ki67 can be used as predictive and prognostic marker in breast cancer patients when integrated with subtypes of breast cancer, specially in triple negative and ER positive cases.
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
2009
Breast cancer is a molecularly heterogeneous disease that appears to include at least four major tumor subtypes ( 1 -3 ). Currently, the choice of adjuvant systemic therapy is based on patient ' s age, tumor size, histological grade, lymph node involvement, hormone receptor status, and HER2 status. The only predictive markers with an associated targeted therapy are the estrogen receptor (ER) and HER2. The approximately 15% of patients with breast cancer who have HER2 overexpressing and/or amplified tumors are treated with a combination of trastuzumab, a monoclonal antibody targeting HER2, and adjuvant chemotherapy ( 4 ). For the two-thirds of breast cancers that are positive for ER and/or progesterone receptor (PR),